EMA Strengthens Postmarket Clinical Trial Reporting Requirements

Drug Industry Daily
A A
Beginning today, new safety and efficacy findings that emerge during postmarket clinical trials should be reported in periodic safety update reports (PSURs) submitted to the European Medicines Agency (EMA).

To View This Article:

Login

Subscribe To Drug Industry Daily